CureVac works to boost production capacity ahead of expected vaccine approval

Berlin: Germany's CureVac expects European approval of its COVID-19 vaccine in June at the latest and is working to expand production capacity, the Augsburger Allgemeine newspaper quoted a company spokeswoman as saying.

Since starting out in 2000, the biotech company has focused on so-called messenger RNA (mRNA), a drug and vaccine technology that has also become the recent focus of the European Union's procurement negotiations. The mRNA approach has been validated by the wide use of coronavirus vaccines developed by pioneers BioNTech and its partner Pfizer, as well as by Moderna, in Europe and North America.